AOD 9604 (5mg)

A single-component research material supplied for controlled research environments. Suitable for studies involving peptide characterization and method development in model systems.

Composition

• AOD 9604
• Appearance: Lyophilized powder in a sealed research vial

Research Focus (non-clinical)

• Peptide identity and purity assessment via HPLC/LC-MS
• Assay development and calibration for quantitative analysis
• Chromatographic method optimization for impurity profiling
• Stability characterization of a lyophilized peptide under laboratory storage conditions

For qualified research professionals and institutional laboratories. Not for human use.

Documentation & Quality Assurance

Each lot is sourced through our verified global supply chain with emphasis on traceability and quality control. We work diligently to obtain and maintain third-party analytical reports (HPLC/LC-MS) and Certificates of Analysis for each batch, as part of our ongoing quality process. These documents are reviewed internally and displayed as they become available. Independent third-party testing is also performed on select lots to confirm identity, purity, and alignment with our internal specifications.

Important Notice

This product is intended for laboratory research use only. It is not intended for human or veterinary use, and must not be used for diagnostic, therapeutic, or clinical purposes.
This material is not a drug, medical device, or dietary supplement, and has not been evaluated by the U.S. Food and Drug Administration.

Quality & Manufacturing

All materials are sourced from carefully vetted domestic and international manufacturing partners who follow quality systems consistent with ISO and cGMP principles. Each supplier is reviewed for reliability, documentation integrity, and transparency in testing.

We require a verified purity of 99% or higher and perform independent third-party spot testing to confirm that select lots meet our internal standards for identity, purity, and composition. Where available, endotoxin testing results are included on Certificates of Analysis to verify laboratory purity; their inclusion is for research quality assessment only and does not imply suitability for human or veterinary use.

All research materials are sealed for integrity and packaged for stability during storage and transport from manufacturing through final delivery.

What It Is

AOD-9604 (also designated Tyr-hGH177-191) is a synthetic 16-amino-acid peptide consisting of the C-terminal hGH177-191 fragment of human growth hormone (a 15-residue sequence) with an additional N-terminal tyrosine residue added for stabilization and cyclized through a disulfide bond between its two cysteine residues.

Research Background

AOD-9604 has been the subject of pre-clinical investigations using in vitro models, rodent models of obesity (including ob/ob mice and beta-3 adrenergic receptor knock-out mice), and non-human primate chronic-toxicology studies in cynomolgus monkeys. In vitro genotoxicology assays documented in the peer-reviewed literature include the Ames test, a chromosomal aberration assay, and a micronucleus assay, in which the compound was reported as non-mutagenic, non-clastogenic, and not inducing a consistent increase in micronuclei. Separately, a 2022 study published in Drug Design, Development and Therapy examined the human growth hormone 176-191 fragment in MCF-7 breast cancer cell cultures alongside molecular docking simulations targeting the estrogen receptor, HER2, and related biomarkers; that study addresses a differently-numbered fragment (176-191) and does not establish it as the same molecule as AOD-9604.

Observed Areas of Interest in Research

Research published in Endocrinology (2001) examined AOD-9604's relationship to the beta-3 adrenergic receptor (beta3-AR) pathway: chronic treatment in obese mice was associated with increased beta3-AR RNA expression, and experiments in beta3-AR knock-out mice were used to probe the compound's dependence on that receptor for observed metabolic effects in those models. Separate work reported in the International Journal of Obesity (2001) documented that AOD-9604 does not compete for binding at the human growth hormone receptor and does not induce cell proliferation, distinguishing its studied mechanistic profile from that of full-length hGH. Pre-clinical pharmacokinetic studies in rats and pigs, described in the Journal of Endocrinology and Metabolism (2014), characterized AOD-9604's rapid enzymatic degradation (an approximately 3-minute plasma half-life after intravenous injection) and sequential N-terminal amino acid removal as the major degradation pathway; in the rat model, that source estimated approximately 40% oral availability from radioactivity distribution (a figure that reflects degradation products rather than intact peptide). A separate line of early-stage in vitro research has explored a C-terminal hGH fragment (numbered 176-191) in MCF-7 cell cultures in the context of cancer-cell biomarkers and nanoparticle drug-delivery systems; the underlying source treats AOD-9604 only as background literature and does not establish the 176-191 fragment as the same molecule.

Research Notes

Purity verified by third-party laboratory analysis (Certificate of Analysis available on request). Supplied strictly for in-vitro and laboratory research use only. Not for human consumption.

All information above is provided for research and educational reference only and summarizes findings from published scientific literature (predominantly in-vitro and animal models). It does not describe outcomes in humans. This product is not a drug, dietary supplement, or article intended for human or veterinary use.

All products from Blitz Health are manufactured using a lyophilization (freeze-drying) process. This method is designed to maintain product integrity and allows vials to remain stable during shipping for approximately 3–4 months.

Once a vial is reconstituted with bacteriostatic water, it should be stored in the refrigerator to help maintain stability. Under these conditions, reconstituted material is generally considered stable for up to 30 days.

Lyophilization is a dehydration technique in which compounds are frozen and then exposed to low pressure. This causes the water in the vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure. This powder can be kept at room temperature until reconstitution.

Upon receipt, products should be stored away from heat and light. For short-term use, refrigeration at approximately 4°C (39°F) is suitable. For long-term storage (several months to years), vials may be placed in a freezer at approximately -80°C (-112°F). Freezing is the preferred method for preserving product stability over extended periods.

⚠️ Important Notice:
These products are intended for research use only. Not for human consumption.